B. Riley lowered the firm’s price target on Denali Therapeutics (DNLI) to $35 from $38 and keeps a Buy rating on the shares following the Q4 report. The company highlighted key corporate priorities aimed at de-risking the path to U.S. FDA approvals for multiple programs within its Enzyme Transport Vehicle franchise, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer
- Denali Therapeutics: Promising Drug Pipeline and Financial Stability Support Buy Rating
- Denali Therapeutics price target lowered to $32 from $33 at Wedbush
- Positive Outlook for Denali Therapeutics: Strategic Progress and Promising Developments Support Buy Rating
- Denali Therapeutics: Promising ETV Platform and Strategic Advancements Justify Buy Rating